Second engine igniting off the first: an unplanned-for adjacent revenue stream has started paying, and management is now
The model's full reasoning — Q1 2018 call → NOWe need answer YES or NO based on transcript. Need determine if management describes second distinct way of making money emerged from existing operations, already generating real paying business, and being deliberately grown. Let's parse transcript. Company Illumina. Core business sequencing instruments/consumables, microarrays. They have services. Need identify second avenue that grew out of first. Possible candidates: Helix? But Helix is separate investment, not from operations? They mention Helix losses, tax benefit. Not second avenue. Microarray business? It's existing segment, not second from sequencing. Sequencing services? They have service and other revenue, including genotyping services, sequencing services, instrument maintenance contracts. Is that a second avenue? It grew from existing capabilities? But it's part of their business. They mention "Microarray service revenue doubled" and "sequencing services" but not as distinct new avenue. Oncology collaborations with pharma: companion diagnostics. They are partnering to create distributable companion diagnostics. This is a new revenue avenue? They mention milestone payments associated with recently announced oncology collaborations included in sequencing and other revenue. This is a second way of making money from existing technology? They are leveraging their sequencing technology and assays to develop companion diagnostics with pharma. It is distinct from selling instruments/consumables. It is already generating? They said no revenue impact in Q1, but guidance includes milestone payments. They are deliberately pursuing more partnerships. But is it "already generating real paying business today"? They said "Milestone payments associated with our recently announced oncology collaborations. These will be included in sequencing and other revenue." And "we haven’t recognized any milestones or contributions from them. We will going forward as these start to take off." So not yet paying? They are signed deals, but no revenue yet. So not "already generating real paying business today" in Q1. They expect future. So NO. Another candidate: Consumer genomics / DTC market driving microarray services. That's existing business. Another: "Illumina will continue to be an important enabler and innovator of sequencing broadly through the system and consumables we bring to market.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
LRN · Q1 2019 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows career readiness as a distinct second revenue avenue that emerged directly from the existing MPS business: students already enrolled in Managed Public Schools are being moved into career readiness programs (over 5,000 students), and the initiative is built on the same platform, curriculum, and student base. Management explicitly describes it as a “career readiness line of business” and “robust career readiness business” that is already generating paying enrollments today while they are deliberately investing resources—dedicated executives, reallocation of funds, and plans to drive a major portion of next year’s enrollment growth.
M · Q4 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Macy’s Marketplace is explicitly described as a distinct new revenue avenue that emerged directly from their existing e-commerce operations and customer base (macys.com, cross-shoppers, and omnichannel platform). Jeff Gennette states it “captures incremental sales opportunity,” “drives a larger average order value,” “allows us to quickly move into new and adjacent categories without inventory risk,” and “attracts a new younger customer,” while management is actively scaling it by adding 2,000 brands in 2023 and launching Bloomingdale’s marketplace in the back half.
GDRX · Q2 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Pharma Manufacturer Solutions is the second distinct revenue avenue that emerged from GoodRx’s existing operations. Trevor explicitly states: “Our distinct ability to reach both consumers and providers continues to be recognized by manufacturers as evidenced by the strong growth.” This capability originated from the core prescription-transactions platform and user base 3 years earlier (when other offerings were only ~5% of revenue). In Q2 2022 it generated $26.6 million (102% YoY growth) and is already producing real paying business.